

File reference	W17F466
Key words	Pharmacy/dermatology
Date of release	28/09/2017
Attachments	No

Freedom of Information Act Disclosure log - Reply Extract

You asked

1. **Is it your Trust/CCG policy to wait until 90 days post NICE guidance to fund new drugs or do they fund earlier?**

It is usual to wait 90 days unless clinical need of the patient requires an early adoption

2. **What is your Trust/CCG policy re use of Zero Risk (ZR)/Early Use Schemes (EUS), i.e. where a medicine is made available free of charge or at a reduced price to the NHS whilst awaiting NICE/SMC approval, in lieu of NICE?**

There is currently no policy but each scheme is assessed for risk, need and cost with the relevant commissioner and approved through the joint risk share group

3. **What is the process for getting such ZR/EUS schemes implemented/approved/signed off within your Trust/hospital? Who needs to sign the contracts for such schemes?**

As above

IFR/Cohort Funding:

FOA: Dermatology Lead Pharmacist / Dermatology Department Clinical Director

1. **What is your Trust's policy re Individual Funding Request and/or Cohort Funding policy? Ref: IFR/Cohort Funding**

This is not a local policy – the Trust follows the national process for IFR and cohort funding

https://www.engage.england.nhs.uk/consultation/af642939/supporting_documents/genericcommissioningpolicies.pdf

2. **Do you have a pathway/preferential prescribing list, illustrating sequential use of Biologics in Dermatology? What does this recommend?**

No

3. **How many lines/trials of biologics are allowed/funded for the management of psoriasis within your trust/CCG? What happens if a clinician needs to exceed this?**

No restriction in place

4. **If there is a biologics psoriasis pathway - how often is it updated to reflect changes to NICE status of new therapies?**

N/A

5. **If there is no formulary/pathway - what do the Trust/CCG utilise in order to guide use of biologics in the management of psoriasis?**

Currently the Trusts Dermatology Pharmacist informs clinicians of the most cost effective biologic

Atopic Dermatitis

FAO: Dermatology Service Manager

1. **How many patients attended for a new outpatient appointment in dermatology Utilising ICD-10 classification - L20 Atopic Dermatitis (Eczema) - from April 2015 - March 2016?**

Information not known, outpatients are not coded.

2. **The number of paediatric attendances of patients utilising ICD-10 classification - L20 for Atopic Dermatitis (Eczema) - from April 2015 - March 2016?**

Information not known, outpatients are not coded.

3. **Does your Trust have a paediatric dermatologist? Does your Trust have a paediatrician with a dermatology interest/specialism?**

The Trust has one Consultant and one Speciality Doctor with a Specialist Interest in Paediatric Dermatology.

Attachments included: No